|
17 Oct 2013 |
International Stem Cell Corporation Announces New Data From Parkinson's Disease Program
|
|
17 Oct 2013 |
Rebiotix Begins Clinical Trial of Therapy for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea
|
|
16 Oct 2013 |
Isis Earns $10 Million Milestone Payment from Biogen Idec for Advancement of ISIS-DMPK Rx to Treat Myotonic Dystrophy
|
|
14 Oct 2013 |
Coronado Biosciences Announces Top-Line Results From Its TRUST-I Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease
|
|
11 Oct 2013 |
Gentium Receives Positive Opinion From EMA's COMP for Defibrotide for the Prevention of GvHD
|
|
09 Oct 2013 |
The Medicines Company and Alnylam Advance Development Candidate for ALN-PCSsc, a Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation for the Treatment of Hypercholesterolemia
|
|
08 Oct 2013 |
Alnylam Advances Development Candidate for ALN-AS1, a Subcutaneously Administered RNAi Therapeutic Targeting Aminolevulinate Synthase 1 (ALAS-1) for the Treatment of Hepatic Porphyrias
|
|
08 Oct 2013 |
Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B
|
|
08 Oct 2013 |
Isis Earns $7 Million in Milestone Payments from GSK for Advancement of ISIS-GSK3 Rx to Treat Viral Infection
|
